Tulisokibart, a monoclonal antibody designed specifically to bind to TL1A, a protein involved in the inflammatory process of ulcerative colitis, proved safe and effective in a phase 2 trial involving patients who had failed other therapies. It is the first drug in its class and would provide a novel treatment pathway for these patients.